Drug intelligence / Profile preview

CX15

Development stage: Preclinical
Lead developer: Hangzhou Bangshun Pharmaceutical
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
Administration: Oral

Overview

CX15 is a preclinical-stage small molecule molecular glue developed by Hangzhou Bangshun Pharmaceutical (Biosun Pharma). It is designed to target Kelch-like ECH-associated protein 1 (KEAP1), a key regulator of the NRF2 signaling pathway often implicated in cancer progression and resistance. The drug is being developed for the treatment of solid tumors, with potential applications as both a monotherapy and in combination regimens. Hangzhou Bangshun Pharmaceutical expects to submit an Investigational New Drug (IND) application for CX15 in 2027.

Other names: CX15 (Molecular Glue)

Targets

KEAP1 (Kelch-like ECH-associated protein 1)

Beyond the preview

Go deeper on CX15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX15.

Explore the full profile